Gut Microbiome and Metabonomic Profile Predict Early Remission to Anti-Integrin Therapy in Patients with Moderate to Severe Ulcerative Colitis
Jie Liu, Huaying Fang, Na Hong, Chaolan Lv, Qihua Zhu, Yinping Feng, Bo Wang, Jiashuang Tian, Yue Yu
Abstract
It is reported that patients with ulcerative colitis (UC) have low response rates to anti-integrin medications in the latest VARSITY study. Therefore, our primary goals were to discover differences in the gut microbiome and metabonomics patterns between early remission and nonremission patients and to explore the diagnostic value in predicting clinical remission to anti-integrin therapy accurately.
Topics & Concepts
Ulcerative colitisMicrobiomeGut microbiomeMedicineColitisInternal medicineGastroenterologyBioinformaticsBiologyDiseaseGut microbiota and healthInflammatory Bowel DiseaseGastrointestinal motility and disorders